Paxlovid Shows No Advantage Over Placebo for Long COVID in Phase II Trial
Source Summary
A large double-blind phase II trial called RECOVER-VITAL found that nirmatrelvir-ritonavir (Paxlovid) was not more effective than placebo at relieving long COVID symptoms. At 90 days, symptoms meaningfully improved in both treatment and placebo groups.
Why it matters
The trial result challenges the use of Paxlovid as a treatment for long COVID, a condition affecting millions of patients with persistent post-infection symptoms.
